tirzepatide for binge eating disorder 504: Adult Disorders in the GLP-1 Era Pharmacotherapies for Binge Eating Disorder:

At 5 mg/mL (1.0 mL water), each 10 units delivers 0.5 mg

Here's how they compare: Semaglutide (GLP-1 agonist) Mechanism: Single-action GLP-1 receptor agonist FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: 15-20% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients starting their weight loss journey seeking proven, well-studied medication Tirzepatide (dual GIP/GLP-1 agonist) Mechanism: Targets both GIP and GLP-1 receptors for enhanced metabolic effect FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: Up to 22% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients seeking more aggressive fat loss with dual-action metabolic support Retatrutide (triple agonist, not yet available) Mechanism: Targets GLP-1, GIP, and glucagon receptors FDA status: Not FDA-approved

Certain conditions can cause your body to make excess melanin that shows up as darker dots, spots or patches on your skin

Focus: Dual-agonist therapies, weight loss efficacy, and better adherence via oral options